Literature DB >> 3690805

Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration.

M W DeGregorio1, B J Wilbur, E Coronado, C K Osborne.   

Abstract

The athymic nude mouse has been used as an in vivo model for pharmacologic studies of the antiestrogen, tamoxifen. We have examined the steady-state serum tamoxifen concentrations achieved in mice with s.c. slow-release pellets, s.c. injections, and i.p. injections, in an attempt to identify a method that would yield serum levels similar to those observed in patients receiving tamoxifen therapy. Tamoxifen and tamoxifen metabolites were examined by a high-performance liquid chromatography assay which has a sensitivity of 8 ng/ml. Tamoxifen metabolites were not observed with any dose or schedule. After slow-release pellets containing 5 or 25 mg tamoxifen no tamoxifen was detectable, even after 2 weeks of treatment. Very low levels (0.07 microM) were found with 50-mg pellets. Tamoxifen was also not detected either with daily s.c. injections of 500 micrograms/mouse or with i.p. injections of 2.5 mg/kg. However, daily s.c. injections of 1000 micrograms or i.p. injections of 25, 50, or 100 mg/kg resulted in tamoxifen concentrations ranging from 0.21 to 0.51 microM which are similar to those observed in patients. Thus, clinically relevant tamoxifen concentrations can be achieved in the nude mouse with either of these methods of administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3690805     DOI: 10.1007/bf00262583

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice.

Authors:  K Seibert; S M Shafie; T J Triche; J J Whang-Peng; S J O'Brien; J H Toney; K K Huff; M E Lippman
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

2.  Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice.

Authors:  H D Soule; C M McGrath
Journal:  Cancer Lett       Date:  1980-08       Impact factor: 8.679

3.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells.

Authors:  R L Sutherland; R E Hall; I W Taylor
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

4.  Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data.

Authors:  C Fabian; L Sternson; M El-Serafi; L Cain; E Hearne
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

5.  Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase.

Authors:  C K Osborne; D H Boldt; G M Clark; J M Trent
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

6.  Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.

Authors:  C K Osborne; K Hobbs; G M Clark
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

7.  Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice.

Authors:  S M Shafie; F H Grantham
Journal:  J Natl Cancer Inst       Date:  1981-07       Impact factor: 13.506

8.  Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice.

Authors:  N Brünner; M Spang-Thomsen; L Vindeløv; J Wolff; S A Engelholm
Journal:  Eur J Cancer Clin Oncol       Date:  1985-11
  8 in total
  7 in total

1.  Tumor and serum tamoxifen concentrations in the athymic nude mouse.

Authors:  M W DeGregorio; E Coronado; C K Osborne
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Tamoxifen administration routes and dosage for inducible Cre-mediated gene disruption in mouse hearts.

Authors:  Kristin B Andersson; Lisbeth H Winer; Halvor K Mørk; Jeffery D Molkentin; Frédéric Jaisser
Journal:  Transgenic Res       Date:  2009-11-06       Impact factor: 2.788

3.  Tamoxifen mechanically reprograms the tumor microenvironment via HIF-1A and reduces cancer cell survival.

Authors:  Ernesto Cortes; Dariusz Lachowski; Benjamin Robinson; Muge Sarper; Jaakko S Teppo; Stephen D Thorpe; Tyler J Lieberthal; Kazunari Iwamoto; David A Lee; Mariko Okada-Hatakeyama; Markku T Varjosalo; Armando E Del Río Hernández
Journal:  EMBO Rep       Date:  2018-12-11       Impact factor: 8.807

4.  Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma.

Authors:  Myra Langendonk; Mathilde R W de Jong; Nienke Smit; Jonas Seiler; Bart Reitsma; Emanuele Ammatuna; Andor W J M Glaudemans; Anke van den Berg; Gerwin A Huls; Lydia Visser; Tom van Meerten
Journal:  Blood Cancer J       Date:  2022-03-07       Impact factor: 11.037

5.  Development of a novel molecular sensor for imaging estrogen receptor-coactivator protein-protein interactions.

Authors:  Madryn C Lake; Quang-Dé Nguyen; Simak Ali; Eric O Aboagye
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

6.  Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice.

Authors:  Danilo C Miguel; Jenicer K U Yokoyama-Yasunaka; Silvia R B Uliana
Journal:  PLoS Negl Trop Dis       Date:  2008-06-11

7.  Analysis of the Ki-67 index in the vaginal epithelium of castrated rats treated with tamoxifen.

Authors:  Afif Rieth Nery-Aguiar; Yousef Qathaf Aguiar; Airton Mendes Conde Júnior; Airlane Pereira Alencar; Cleciton Braga Tavares; Pedro Vitor Lopes-Costa; Afonso Celso Nazário; Benedito Borges da Silva
Journal:  Clinics (Sao Paulo)       Date:  2016-02       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.